MMP-2 and Breast Cancer Survival
Author Information
Author(s): Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T
Primary Institution: University of Oulu
Hypothesis
Does MMP-2 negativity in primary breast carcinoma correlate with better survival outcomes in high-risk patient groups?
Conclusion
MMP-2 negativity is associated with a significantly better prognosis in breast carcinoma patients.
Supporting Evidence
- 78% of primary breast carcinoma tumors showed MMP-2 positivity.
- 10-year overall survival was 72% for MMP-2 positive patients compared to 77% for MMP-2 negative patients.
- All node-negative patients with MMP-2 negativity were alive after 10 years.
Takeaway
If a breast cancer patient has low levels of a protein called MMP-2, they might have a better chance of surviving their cancer.
Methodology
The study analyzed breast tissue samples from 453 patients, assessing MMP-2 expression and correlating it with survival outcomes.
Potential Biases
Potential bias in patient selection and treatment protocols could affect the results.
Limitations
The study may not generalize to all breast cancer patients due to the over-representation of node-positive cases.
Participant Demographics
Patients aged 26-85, median age 52, with a predominance of ductal infiltrating carcinoma.
Statistical Information
P-Value
0.03
Confidence Interval
1.10–2.88
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website